Oral Micronized Progesterone for Adolescents (Ages 12 to 17): Transitioning to Adult Care

Why Oral Micronized Progesterone Matters for Teen Girls

Progesterone is the hormone that builds and then sheds the uterine lining at the end of each menstrual cycle. In adolescents, the first two to three years after the first period are almost always anovulatory, meaning the ovary releases an egg irregularly or not at all. Without ovulation, the body produces very little progesterone on its own. The lining keeps building under estrogen stimulation, and the result is unpredictable, sometimes very heavy, sometimes completely absent bleeding.

Oral micronized progesterone (Prometrium) is a plant-derived, body-identical form of progesterone. It is chemically identical to the progesterone your ovaries make, which is one reason it is preferred over older synthetic progestins for many adolescent conditions. That chemical identity matters for tolerability: synthetic progestins such as medroxyprogesterone acetate carry androgenic side effects (acne, mood changes) that can be particularly unwanted in a teenage girl already navigating hormonal changes.

About 70% of menstrual cycles in the first two years after menarche are anovulatory, according to data published in the Journal of Pediatric and Adolescent Gynecology. This high baseline rate means that irregular periods in a 13-year-old are rarely pathological on their own. The clinical question your provider is answering is: does this teen need progesterone supplementation to protect her uterine lining, regulate withdrawal bleeds, or address a specific diagnosis like PCOS or primary ovarian insufficiency (POI)?

What "Body-Identical" Means for a Developing Body

The term "body-identical" or "micronized" simply describes how the progesterone molecule is processed. Micronization breaks the hormone into tiny particles that absorb better through the gut wall. Because the molecule itself is identical to endogenous progesterone, it binds only to progesterone receptors and does not activate androgen receptors the way older synthetic progestins do. For an adolescent with hormonal acne or a teen with PCOS who already has elevated androgens, this selectivity is clinically relevant.

Conditions in Adolescents That May Prompt a Prescription

Several distinct diagnoses in the 12 to 17 age group may lead a provider to prescribe oral micronized progesterone.

• Anovulatory dysfunctional uterine bleeding (DUB): Irregular, sometimes heavy periods caused by cycles that do not include ovulation.
• PCOS: Polycystic ovary syndrome affects approximately 6 to 12% of reproductive-age females in the US. Infrequent or absent periods are a hallmark, and cyclic progesterone is one strategy for protecting the endometrium from unopposed estrogen exposure.
• Functional hypothalamic amenorrhea (FHA): Common in teenage athletes and girls with restrictive eating, FHA causes the brain to suppress ovulation signaling. Progesterone withdrawal bleeds are sometimes used to reassure that the outflow tract is intact, though treatment of the underlying energy deficit is the true fix.
• Primary ovarian insufficiency (POI): Rare in adolescents but documented; girls with Turner syndrome or other genetic conditions may need full hormone replacement that includes progesterone alongside estrogen.
• Gender-affirming care: Some transgender adolescents assigned female at birth may be prescribed progesterone as part of their hormone protocol; dosing and goals differ from cisgender applications and must be managed by a specialist.

Dosing in Adolescents: What Differs from Adult Guidelines

Adult dosing for Prometrium is grounded in the FDA-approved label for postmenopausal women receiving estrogen therapy. That label specifies 400 mg orally at bedtime for 10 days per 28-day cycle when used to prevent endometrial hyperplasia. Adolescent dosing is extrapolated from adult data because no dedicated randomized trials in the 12 to 17 age group exist for this drug. Providers typically use 200 to 400 mg nightly for 10 to 14 days of each calendar month.

Why the Dose Is Given at Bedtime

Oral micronized progesterone causes sedation. This is not a bug; for many women it is a feature. Progesterone converts in the gut and liver to a metabolite called allopregnanolone, which acts on GABA-A receptors in much the same way a mild sedative does. Giving the dose at bedtime turns a side effect into an advantage: the teen sleeps better and wakes with no noticeable drowsiness. Taking it in the morning is a common mistake during the transition period when a new pharmacist or prescriber fills the script without noting this detail.

Absorption and the Role of Food

Taking oral micronized progesterone with a small amount of food, particularly something with a little fat, increases bioavailability by roughly 40% compared with fasting. A glass of whole milk or a small handful of nuts at bedtime is sufficient. This is a practical detail that gets lost in transition if the new provider or pharmacy counselor does not mention it.

Cycle Length Monitoring

In adolescents with anovulatory cycles, the goal of cyclic progesterone therapy is to induce a scheduled withdrawal bleed every 4 to 8 weeks, protecting the uterine lining from prolonged unopposed estrogen stimulation. If a teen goes more than 90 days without any bleed, ACOG recommends evaluation to rule out pregnancy and other secondary causes of amenorrhea before continuing or adjusting progesterone therapy.

Transitioning from Pediatric to Adult Care: The Clinical Handoff

The move from a pediatric gynecologist or adolescent-medicine provider to an adult women's-health practice is one of the highest-risk moments for medication errors, missed follow-up, and loss of established diagnoses from the medical record. Studies of adolescents with chronic conditions find that up to 30% experience a gap in care of at least one year during the transition period, and that gap is associated with worse long-term disease control.

The WomanRx Adolescent Progesterone Transfer Checklist below identifies the six items most commonly dropped during pediatric-to-adult handoffs for girls on oral micronized progesterone. Providers at WomanRx use this checklist during first adult visits when a teen presents with progesterone already on her medication list.

The Six-Point Transfer Checklist

1. Diagnosis confirmation. The adult provider should review the original indication. "Irregular periods" is not a diagnosis. The chart should state PCOS, FHA, POI, or anovulatory DUB with supporting labs.
2. Peanut allergy re-screening. Prometrium capsules are formulated in peanut oil. This must be confirmed at every prescribing event, not just at initiation.
3. Pregnancy status and contraception review. Any sexually active adolescent needs a pregnancy test before each new course. If she is at risk of pregnancy and the progesterone is not being used as luteal support, contraception counseling is mandatory.
4. Bedtime dosing instruction. As noted above, this detail is frequently omitted by new pharmacies.
5. Food-with-dose instruction. Bioavailability drops significantly on an empty stomach.
6. Follow-up bleed diary. The teen should bring a cycle tracking record (a phone app is acceptable) to her first adult appointment so the new provider can see the pattern over the past 6 to 12 months, not just a verbal summary.

What the Teen Should Bring to Her First Adult Appointment

A paper or digital summary card works better than asking the adolescent to narrate her history. The card should include: original diagnosis, dose and schedule, date of last withdrawal bleed, any side effects noted, name of pediatric provider, and most recent lab results (ideally testosterone, LH, FSH, estradiol, TSH, and prolactin if PCOS or amenorrhea was the indication).

The Role of the Shared Visit

Some pediatric programs offer a shared visit model: the pediatric and adult provider both see the patient together once, then the pediatric provider signs off. This model has been shown to reduce missed follow-up in adolescents with chronic conditions by roughly 50% in a 2017 study in the Journal of Adolescent Health. If your current provider offers this, take it. If not, ask. WomanRx clinicians can coordinate a written handoff letter with the pediatric team on request.

Sex-Specific Physiology: How Progesterone Behaves in an Adolescent Female Body

Adolescent females are not simply smaller adults. Several physiological differences affect how oral micronized progesterone behaves in girls aged 12 to 17.

Hepatic First-Pass Metabolism

The liver is the primary site where oral progesterone is converted to active and inactive metabolites. In early puberty, hepatic enzyme activity (specifically CYP3A4) is still maturing. This means progesterone exposure from the same oral dose can be higher in a younger or smaller adolescent than in an adult woman of average weight. Providers prescribing to girls under 14 or with a body weight below 45 kg typically start at 200 mg rather than 400 mg for this reason, though controlled pharmacokinetic studies in this population are limited.

The Hypothalamic-Pituitary-Ovarian Axis Is Not Fully Mature

A teen's HPO axis is still calibrating. Exogenous progesterone given cyclically does not suppress the axis the way combined hormonal contraceptives do. This means the teen keeps whatever spontaneous cycle activity her axis is generating, and the withdrawal bleed from progesterone is layered on top of it. Occasionally this creates a confusing bleed pattern (two bleeds in one month, for example) that alarms both the teen and her new provider. Knowing this in advance prevents unnecessary testing.

Body Composition and Drug Distribution

Progesterone is highly lipophilic. Adolescent girls have a higher percentage of body fat than adult women in many age groups, which increases the volume of distribution for fat-soluble drugs. In practice, this may mean that peak blood levels are lower but the drug persists longer. No specific dose adjustment is recommended based on body composition alone, but it is a reason to monitor symptom response rather than relying on serum progesterone levels, which are not clinically useful for oral micronized progesterone (serum levels after oral dosing reflect metabolites, not tissue activity).

Pregnancy, Lactation, and Contraception: Required Reading

This section is mandatory reading for any sexually active adolescent or the parent or guardian of a teen who may become sexually active.

Pregnancy

Oral micronized progesterone is not a contraceptive. It will not prevent pregnancy. Prometrium carries an FDA label warning against use in the first trimester of pregnancy except under specific clinical circumstances such as luteal-phase support in assisted reproduction. Animal studies have shown fetal harm at high doses, and first-trimester exposure in humans has not been adequately studied. The label does not assign a formal letter category under the old system, but it explicitly states that the drug should be used in pregnancy only if the potential benefit justifies the potential risk.

A urine pregnancy test should be done before starting each 10-to-14-day course. This is not optional for sexually active patients. If a pregnancy test comes back positive, the teen needs immediate contact with her provider. She should not start or continue a withdrawal-bleed course of progesterone while a pregnancy test is positive.

The situation is different if the progesterone has been prescribed as luteal-phase support following an embryo transfer or insemination, a scenario rare in this age group but not impossible in older adolescents undergoing fertility treatment. In that specific context, progesterone supplementation through the first 10 to 12 weeks of pregnancy is standard practice according to the American Society for Reproductive Medicine.

Lactation

Oral micronized progesterone does transfer into breast milk. Progesterone appears in human milk at low concentrations, but data specifically on infant outcomes from maternal oral micronized progesterone use during lactation are limited. For most adolescents, lactation is not relevant. For a postpartum teen who is breastfeeding and was on progesterone before pregnancy, this should be discussed explicitly with her adult provider before restarting.

Contraception Requirement

Because oral micronized progesterone does not prevent pregnancy and because some of the conditions it is used to treat (PCOS, FHA recovery) may involve unexpected ovulation as the underlying condition improves, ACOG recommends that sexually active teens on cyclic progesterone for menstrual management also use a reliable contraceptive method unless the progesterone itself is part of an intentional conception plan.

Long-acting reversible contraceptives (LARCs) such as the hormonal IUD or the subdermal implant are the methods with the highest efficacy for this age group. A hormonal IUD containing levonorgestrel provides endometrial protection on its own and may eliminate the need for cyclic oral progesterone in girls whose primary indication was preventing endometrial buildup. This is a conversation worth having with the adult provider at the first transfer visit.

Who This Is Right For and Who Should Think Twice

Life Stages and Conditions Where Oral Micronized Progesterone Makes Sense

• Adolescents with confirmed PCOS who have infrequent periods (fewer than 8 cycles per year) and want to avoid combined oral contraceptives for personal, medical, or cultural reasons.
• Teens with anovulatory DUB who do not need contraception and whose primary need is cycle regulation and endometrial protection.
• Girls with POI or Turner syndrome on estrogen replacement who need progesterone to complete their hormone replacement protocol.
• Teens and young adults with a history of migraine with aura, for whom estrogen-containing contraceptives carry a stroke risk and who need a progestogen-only option for cycle management. Note: progestogen-only pills containing norethindrone are also an option; the choice between them depends on the clinical picture.

Situations That Warrant Caution or a Different Approach

• Peanut allergy. This is absolute. A teen with a confirmed peanut allergy must not take Prometrium in any dose. Compounded progesterone in a non-peanut-oil base is an alternative but is not FDA-approved and introduces its own quality concerns.
• Active liver disease. Oral progesterone undergoes extensive hepatic metabolism. Teens with significant liver disease (rare but seen in conditions like Wilson disease) may not metabolize the drug predictably.
• Thrombophilia with active symptoms. Progesterone in pharmacological doses has some effect on coagulation factors, though the risk from oral micronized progesterone appears lower than from synthetic progestins. A teen with a known clotting disorder needs individualized risk assessment.
• Teens who need contraception. Oral micronized progesterone does not reliably suppress ovulation at the doses used for cycle management. A teen who is sexually active and needs contraception should discuss a method that addresses both goals simultaneously.

Side Effects Specific to Adolescents

The sedation effect described above is the most commonly reported side effect and is almost always manageable with bedtime dosing. Other effects reported in adult trials that are relevant to teens include:

• Mood changes: The PEPI trial and subsequent observational data suggest oral micronized progesterone has a more favorable mood profile than medroxyprogesterone acetate in adult women. Adolescents with pre-existing anxiety or depression should be monitored at follow-up, but oral micronized progesterone is generally considered less mood-new than synthetic progestins.
• Breast tenderness: Progesterone stimulates the breast glandular tissue. Teens, whose breasts are still developing, may notice temporary tenderness in the second half of the progesterone course.
• Bloating and water retention: These are cycle-phase symptoms amplified by the progesterone dose and typically resolve within 2 to 3 days of stopping the course.
• Dizziness if taken upright: The sedating metabolite allopregnanolone can cause dizziness if the teen takes the pill and then stays upright for 30 minutes. She should take it lying down and plan to sleep within 20 to 30 minutes.

A 2019 Cochrane review of progestogen therapy for irregular uterine bleeding found no serious adverse events attributable to cyclic oral progestogen use in the trials reviewed, though the review noted the evidence base is moderate quality overall.

Evidence Gaps: What We Know and What We Are Extrapolating

Women and girls have been chronically under-represented in drug trials. For oral micronized progesterone specifically, the FDA-approval trials enrolled postmenopausal women. Every application to adolescents is extrapolated, not directly studied. No phase III randomized controlled trial has compared oral micronized progesterone to placebo in girls aged 12 to 17 for any of the indications listed above. This is not a reason to avoid a drug with decades of adult safety data, but it is a reason to:

1. Treat the adolescent as an individual, not just a small adult.
2. Monitor response and side effects at every visit rather than assuming the adult data maps perfectly.
3. Re-evaluate the indication annually. A teen who needed progesterone at 14 for anovulatory cycles may have a fully mature HPO axis by 17 and no longer need it.

The American College of Obstetricians and Gynecologists notes that the menstrual cycle is a vital sign. Any intervention affecting it in adolescents should be re-evaluated with that framing: is the treatment addressing a real pathology, or normalizing a biological signal that the body is still calibrating?

Practical Steps for the Transition Appointment

Your first adult appointment should accomplish specific things. Walk in prepared.

Before the visit:

• Download 6 to 12 months of cycle data from your tracking app or write out bleed dates on paper.
• Gather your last lab results (testosterone, LH, FSH, estradiol, TSH, prolactin).
• Write down your original diagnosis and when it was made.
• Note any side effects you have experienced and at what point in the course they occur.

At the visit, ask these specific questions:

• "Is my original diagnosis still the right one, or do you see anything in my history that suggests a different picture?"
• "Do I still need this medication, or has my cycle pattern changed enough to try a medication break?"
• "If I become sexually active, what contraceptive method would work alongside this prescription?"
• "What is your protocol for checking on me after I start each course? Is there a nurse line or secure message option?"

After the visit:

• Confirm the pharmacy has your new provider's information.
• Check that the new prescription says "at bedtime with food."
• Schedule the follow-up before you leave. Do not leave without a date on the calendar.

The transition from pediatric to adult care is a seam in the healthcare system where things fall through. Oral micronized progesterone is a medication with a narrow correct-use window: right diagnosis, right dose, right schedule, right contraception plan alongside it. Coming to your first adult visit prepared, with records and specific questions, is the single most effective thing you can do to make sure nothing is lost in the handoff.